Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.48 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.48 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.48 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.48 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL27833573 | 0.97 | TSHR (0.62) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL18987140 | 0.90 | TSHR (0.71) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Mucic Acid SCHEMBL6672352 | 0.88 | PDE4A (0.56) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL27745708 | 0.88 | TSHR (0.59) | TSHRTDP1GPR84FFAR1PDE4A | |
| Tartaric Acid SCHEMBL30771976 | 0.87 | TSHR (0.67) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL282045 | 0.87 | TSHR (0.67) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL8550409 | 0.85 | GPR84 (0.62) | TSHRTDP1GPR84FFAR1PDE4A | |
| Cadaverine Tartrate SCHEMBL21145233 | 0.85 | TSHR (0.56) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Cadaverine Tartrate SCHEMBL7264837 | 0.85 | TSHR (0.56) | TSHRHDAC1HDAC2CHRM1AKR1A1 | |
| Tartaric Acid SCHEMBL29438805 | 0.85 | TSHR (0.56) | TSHRHDAC1HDAC2CHRM1AKR1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739050-B2 | Method for purification of terpenoid amino alcohol derivatives | SCI PHARMTECH INC. (TW) | 2023-08-29 | — | — | US | claimed |
| US-20230103071-A1 | METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVES | SCI PHARMTECH INC. (TW) | 2023-03-30 | — | — | US | claimed |
| EP-4144717-A1 | METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVES | SCI Pharmtech Inc (TW) | 2023-03-08 | — | — | EP | claimed |
| US-8513427-B2 | Compounds for producing substituted sulfoxides, process for producing the same and use thereof | MATRIX LABORATORIES LIMITED (IN) | 2013-08-20 | — | — | US | claimed |
| EP-2342193-B1 | NOVEL COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | MATRIX LAB LTD (IN) | 2013-06-05 | — | — | EP | claimed |
| US-20110184182-A1 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2011-07-28 | — | — | US | claimed |
| EP-2342193-A2 | NOVEL COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Matrix Laboratories Limited (IN) | 2011-07-13 | — | — | EP | claimed |
| WO-2010035283-A2 | NOVEL COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | MATRIX LABORATORIES LIMITED (IN) | 2010-04-01 | — | — | WO | claimed |
| CN-1180702-C | Donkey-hide gelatin coffee | 庞 滨 | 2004-12-22 | — | — | CN | claimed |
| CN-1433700-A | Donkey-hide gelatin coffee | PANG BIN (CN) | 2003-08-06 | — | — | CN | claimed |
| WO-2025007888-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | 沈阳兴齐眼药股份有限公司 | 2025-01-09 | — | — | WO | disclosed |
| EP-3689324-B1 | NEW COOLING AGENTS AND PREPARATIONS COMPRISING THEM | SYMRISE AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| EP-4282853-A1 | PROCESS FOR THE PREPARATION OF MESACONIC ACID ESTERS | Symrise AG (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-11739050-B2 | Method for purification of terpenoid amino alcohol derivatives | SCI PHARMTECH INC. (TW) | 2023-08-29 | — | — | US | disclosed |
| US-20230103071-A1 | METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVES | SCI PHARMTECH INC. (TW) | 2023-03-30 | — | — | US | disclosed |
| CN-1180702-C | Donkey-hide gelatin coffee | 庞 滨 | 2004-12-22 | — | — | CN | disclosed |
| CN-1433700-A | Donkey-hide gelatin coffee | PANG BIN (CN) | 2003-08-06 | — | — | CN | disclosed |
| CN-1200666-A | Deodorant product comprising cationic biopolymer, aluminum chloride hydrate and esterase inhibitor | HENKEL KOMMANDITGENSELLSCHAFT (DE) | 1998-12-02 | — | — | CN | disclosed |
| US-5508408-A | LEUKOTRIENE ANTAGONISTS | CIBA-GEIGY CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0298695-A2 | Tartaric acid amide derivative and method of producing the same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1989-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739050-B2 | Method for purification of terpenoid amino alcohol derivatives | ADH1A, MSMO1, MED1 | CHRM1 2527/4885CHRM3 3119/4885HTR2A 2981/4885 |
| US-20110184182-A1 | COMPOUNDS FOR PRODUCING SUBSTITUTED SULFOXIDES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | SQOR, SMOX, CBS | CHRM1 3812/4885CHRM3 3169/4885HTR2A 2600/4885 |
| US-20230103071-A1 | METHOD FOR PURIFICATION OF TERPENOID AMINO ALCOHOL DERIVATIVES | ADH1A, MSMO1, MED1 | CHRM1 2527/4885CHRM3 3119/4885HTR2A 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.